基蛋生物收盘上涨1.60%，滚动市盈率22.35倍，总市值45.14亿元

Group 1 - The core viewpoint of the articles highlights the current financial performance and market position of 基蛋生物, indicating a significant decline in revenue and profit compared to the previous year [1][2] - As of August 19, 基蛋生物's closing stock price was 8.9 yuan, with a PE ratio of 22.35, marking a new low in 165 days, and a total market capitalization of 4.514 billion yuan [1] - The average PE ratio for the medical device industry is 59.49, with a median of 40.19, positioning 基蛋生物 at 46th place within the industry [1][2] Group 2 - For the first quarter of 2025, 基蛋生物 reported revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24% year-on-year, with a gross margin of 77.15% [1] - The company is primarily engaged in the research, production, sales, and service of in vitro diagnostic reagents and instruments, being a key supplier in the POCT field in China [1] - As of March 31, 2025, 基蛋生物 had 26,747 shareholders, a decrease of 451 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]